Acelity said today it launched its Prevena Duo incision management system in the US.
The Prevena Duo is a single use negative pressure wound therapy system specifically designed for the simultaneous management of 2 closed surgical incisions, the San Antonio, Texas-based company said, claiming it is the 1st such product of it’s kind.
The system is designed to reduce post-operative complications in bilateral procedures, including vascular harvesting, breast reconstruction and orthopedic trauma surgeries.
“SSIs encompass more than 20 percent of all HAIs and represent a significant burden both financially and psychologically for the patient, so there is a need to proactively address this issue. With the Prevena Incision Management System, surgeons can rely upon a significant body of clinical evidence demonstrating the system’s efficacy and coupled with its ease of use, ensures that we are doing all we can to help reduce this burden in an effort to improve outcomes for patients,” Dr. Allen Gabriel of PeaceHealth Medical Group Plastic Surgery said in a prepared statement.
Acelity touted that clinical studies of the Prevena system reported a significant reduction in the incidence rate of infection, including a study which reported a 6% rate of infection in groin wound treatment when the system was used, compared to 30% in the control group.
“We are finding that surgeons around the world are adopting Prevena Therapy as standard practice to provide care for their post-operative patients. With the introduction of the Prevena Duo Platform, Acelity is able to provide the same proven clinical benefits of negative pressure therapy that is specially configured for procedures where there are two closed incisions on the patient. Until now, clinicians did not have the option to manage two incisions simultaneously with a single, disposable negative pressure source. The new Prevena Duo Platform offers one efficient, easy-to-use method for providing therapy to these patients,” Acelity chief medical officer Dr. Ron Silverman said in a press release.
The deal brings LifeCell’s regenerative medicine and reconstructive portfolio to Allergan, joining a portfolio of medical aesthetics, breast implant and tissue expander product lines.